Cargando…

South African hypertension practice guideline 2014

OUTCOMES: Extensive data from many randomised, controlled trials have shown the benefit of treating hypertension (HTN). The target blood pressure (BP) for antihypertensive management is systolic < 140 mmHg and diastolic < 90 mmHg, with minimal or no drug side effects. Lower targets are no long...

Descripción completa

Detalles Bibliográficos
Autores principales: Seedat, YK, Rayner, BL, Veriava, Yosuf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Clinics Cardive Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327181/
https://www.ncbi.nlm.nih.gov/pubmed/25629715
http://dx.doi.org/10.5830/CVJA-2014-062
_version_ 1782357026687418368
author Seedat, YK
Rayner, BL
Veriava, Yosuf
author_facet Seedat, YK
Rayner, BL
Veriava, Yosuf
author_sort Seedat, YK
collection PubMed
description OUTCOMES: Extensive data from many randomised, controlled trials have shown the benefit of treating hypertension (HTN). The target blood pressure (BP) for antihypertensive management is systolic < 140 mmHg and diastolic < 90 mmHg, with minimal or no drug side effects. Lower targets are no longer recommended. The reduction of BP in the elderly should be achieved gradually over one month. Co-existent cardiovascular (CV) risk factors should also be controlled. BENEFITS: Reduction in risk of stroke, cardiac failure, chronic kidney disease and coronary artery disease. RECOMMENDATIONS: Correct BP measurement procedure is described. Evaluation of cardiovascular risk factors and recommendations for antihypertensive therapy are stipulated. Lifestyle modification and patient education are cornerstones of management. The major indications, precautions and contra-indications are listed for each antihypertensive drug recommended. Drug therapy for the patient with uncomplicated HTN is either mono- or combination therapy with a low-dose diuretic, calcium channel blocker (CCB) and an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB). Combination therapy should be considered ab initio if the BP is ≥ 160/100 mmHg. In black patients, either a diuretic and/or a CCB is recommended initially because the response rate is better compared to an ACEI. In resistant hypertension, add an alpha-blocker, spironolactone, vasodilator or β-blocker. VALIDITY: The guideline was developed by the Southern African Hypertension Society 2014©.
format Online
Article
Text
id pubmed-4327181
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Clinics Cardive Publishing
record_format MEDLINE/PubMed
spelling pubmed-43271812015-04-10 South African hypertension practice guideline 2014 Seedat, YK Rayner, BL Veriava, Yosuf Cardiovasc J Afr Review Article OUTCOMES: Extensive data from many randomised, controlled trials have shown the benefit of treating hypertension (HTN). The target blood pressure (BP) for antihypertensive management is systolic < 140 mmHg and diastolic < 90 mmHg, with minimal or no drug side effects. Lower targets are no longer recommended. The reduction of BP in the elderly should be achieved gradually over one month. Co-existent cardiovascular (CV) risk factors should also be controlled. BENEFITS: Reduction in risk of stroke, cardiac failure, chronic kidney disease and coronary artery disease. RECOMMENDATIONS: Correct BP measurement procedure is described. Evaluation of cardiovascular risk factors and recommendations for antihypertensive therapy are stipulated. Lifestyle modification and patient education are cornerstones of management. The major indications, precautions and contra-indications are listed for each antihypertensive drug recommended. Drug therapy for the patient with uncomplicated HTN is either mono- or combination therapy with a low-dose diuretic, calcium channel blocker (CCB) and an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB). Combination therapy should be considered ab initio if the BP is ≥ 160/100 mmHg. In black patients, either a diuretic and/or a CCB is recommended initially because the response rate is better compared to an ACEI. In resistant hypertension, add an alpha-blocker, spironolactone, vasodilator or β-blocker. VALIDITY: The guideline was developed by the Southern African Hypertension Society 2014©. Clinics Cardive Publishing 2014 /pmc/articles/PMC4327181/ /pubmed/25629715 http://dx.doi.org/10.5830/CVJA-2014-062 Text en Copyright © 2010 Clinics Cardive Publishing http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Seedat, YK
Rayner, BL
Veriava, Yosuf
South African hypertension practice guideline 2014
title South African hypertension practice guideline 2014
title_full South African hypertension practice guideline 2014
title_fullStr South African hypertension practice guideline 2014
title_full_unstemmed South African hypertension practice guideline 2014
title_short South African hypertension practice guideline 2014
title_sort south african hypertension practice guideline 2014
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327181/
https://www.ncbi.nlm.nih.gov/pubmed/25629715
http://dx.doi.org/10.5830/CVJA-2014-062
work_keys_str_mv AT seedatyk southafricanhypertensionpracticeguideline2014
AT raynerbl southafricanhypertensionpracticeguideline2014
AT veriavayosuf southafricanhypertensionpracticeguideline2014